Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:27:17.345Z.
Calculation as of: 2026-10-06T16:27:17.345Z.
Quote observation: 2026-10-06T16:24:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$24.44M
EV/EBITDA Ratio
N/A
TTM Avg
11456.84x
3Y Avg
11456.84x
5Y Avg
11456.84x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $26.78M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $26.27M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.70M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.50M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.44M | N/A | 11456.84x | 11456.84x | 11456.84x |
| Kyntra Bio, Inc. (KYNB)vs › | $24.38M | N/A | 70.33x | 70.33x | 70.33x |
| OneMedNet Corporation (ONMD)vs › | $29.62M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.51M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.59M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
